Aarhus, Denmark, 17 June 2026 – NMD Pharma A/S, a clinical-stage biotechnology company dedicated to developing novel therapies to restore skeletal muscle health, today announces that further safety and efficacy data from its Phase 2a SYNAPSE-CMT exploratory study evaluating ignaseclant in patients living with Charcot-Marie-Tooth disease (CMT) types 1 or 2 has been presented in a late-breaking oral presentation at the 2026 Peripheral Neuroscience Association (PNS) Annual Meeting held in Maastricht, The Netherlands from June 13-16, 2026. The late-breaking presentation was given by David Herrmann, MD, Chief of the Neuromuscular Division and Vice Chair for Strategic Initiatives in the Department of Neurology at the University of Rochester Medical Center on Sunday, June 14, 2026.
